| Similar Articles |
|---|
 |
The Motley Fool
June 28, 2005
Charly Travers |
Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note.   |
Chemistry World
July 15, 2010
Matt Wilkinson |
Biotechs plot path of least resistance Biopharmaceutical companies are moving into antibiotics, and filling the void left by big pharma. |
The Motley Fool
October 20, 2006
Brian Lawler |
Cubist Paints a Greener Picture The pharmaceutical company is flush with cash and finally profitable. However, it might just be easier for Cubist to sell itself to a more substantial pharmaceutical company. Investors, take note. |
The Motley Fool
December 5, 2006
Brian Lawler |
Cubist Finds an Asian Partner The smaller drug developer teams up with AstraZeneca to bring its antibiotic to worldwide markets. The best part of the deal is that Cubist retains the rights to Cubicin in Japan, which is by far the biggest market in all of Asia. Investors, take note. |
Pharmaceutical Executive
October 1, 2008
Michael Bonney |
Specialty Sales Gets No Resistance The author, a Cubist Pharmaceuticals CEO. has given his company a successful start and is now predicting the future of drug resistance. |
The Motley Fool
October 27, 2004
Charly Travers |
Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug. |
The Motley Fool
April 8, 2005
Brian Gorman |
Cubist in Neutral Cubist Pharmaceuticals' pipeline may be why investors are unimpressed. |
The Motley Fool
July 3, 2008
Brian Lawler |
A Cubist Masterstroke Cubist Pharmaceuticals, until now a one-drug wonder, becomes a marketer of two compounds. |
The Motley Fool
January 13, 2004
David Nierengarten |
Vicuron's Booster Shot With a new "super-tough" antibiotic, Vicuron's stock is super high. |
The Motley Fool
July 20, 2006
Brian Lawler |
Cubist's Square Results The pharmaceutical company has a promising new drug, but little else in the pipeline. Investors, take note. |
BusinessWeek
October 29, 2007
Catherine Arnst |
Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal. |
Chemistry World
April 27, 2011
Carol Stanier |
Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life. |
Chemistry World
August 11, 2014
Phillip Broadwith |
Single shot antibiotic approved for skin infections Intravenous antibiotic Orbactiv oritavancin, from US firm The Medicines Company, has been approved by the US Food and Drug Administration. |
The Motley Fool
January 26, 2005
Charly Travers |
Call Cubist in the Morning Strong drug sales provide a dose of good medicine for this pharmaceutical. |
Chemistry World
December 11, 2014 |
Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin). |
The Motley Fool
April 6, 2011
Brian Orelli |
Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years. |
HHMI Bulletin
Nov 2010
Sarah C.P. Williams |
A Study on Antibiotic Resistance Shows That Bacteria Aren't Just Out To Help Themselves Microbes that are resistant to the drug protect their weaker kin in the colony, HHMI researchers have found. The discovery upends traditional notions of antibiotic resistance and offers a target for new drugs against bacterial infections. |
The Motley Fool
October 20, 2011
Travis Hoium |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Shares of Cubist Pharmaceuticals jumped 10% today after the company released earnings. |
Chemistry World
January 30, 2015
Rebecca Trager |
Billion dollar package unveiled to fight antibiotic resistance President Obama has made a huge investment in the fight against antibiotic resistant bacteria |
AskMen.com
Harold Russell |
The Lowdown On Superbugs The overuse and misuse of antibiotics has led to the development of resistant strains of bacteria, commonly referred to as superbugs. |
American Family Physician
January 15, 2004 |
Antibiotics: When They Can and Can't Help What are antibiotics?... Do antibiotics work against all infections?... What is "antibiotic resistance"?... Why should I worry about antibiotic resistance?... How do I know when I need antibiotics?... How should I take the antibiotics that my doctor prescribes?... etc. |
American Family Physician
September 15, 2006 |
When Antibiotics Can Help A consumer's guide: What are antibiotics?... How do antibiotics work?... What is antibiotic resistance?... How can I prevent antibiotic resistance?... |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
American Family Physician
March 15, 2001 |
Avoiding Resistance to Antibiotics-- When Do I Need an Antibiotic? When bacteria are exposed to the same antibiotics, after a while the antibiotic can't fight the germs anymore... |
Nutrition Action Healthletter
May 2000 |
Magic Bullets Under Siege ...Antibiotics---drugs that kill bacteria---account for much of our success in the war against infectious illness. But the miracle drugs of medicine are in danger... |
Chemistry World
May 6, 2014
Andy Extance |
WHO raises alarm on deadly bacteria The World Health Organization has warned antibiotic resistant bacteria could bring a nightmarish future, where seemingly trivial scrapes turn lethal, and currently routine operations become too risky to contemplate. |
Chemistry World
February 11, 2011
Leanne Marle |
Fighting back against antibiotic resistant bacteria Scientists in Japan have revealed how vancomycin dimers are effective against vancomycin-resistant bacteria. |
The Motley Fool
May 29, 2009
Brian Orelli |
The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin. |
Chemistry World
March 13, 2013
Ned Stafford |
Antibiotic resistance is a 'ticking time bomb' Global research efforts to develop new antibiotics need to be accelerated urgently, the UK government's chief medical officer has warned. She adds that that new drugs are desperately needed to fight the 'catastrophic threat' of growing antimicrobial resistance. |
American Family Physician
October 1, 2006 |
Antibiotics: When They Can and Can't Help What are antibiotics?... Do antibiotics always work?... What is bacterial resistance?... What can I do to help myself?... etc. |
BusinessWeek
April 12, 2004
Catherine Arnst |
Killer Staph Is Hitting The Streets For the past 30 years, hospitals have been battling a mutant form called methicillin-resistant S. aureus (MRSA) that is resistant to penicillin-related antibiotics and is especially lethal. Now it's showing up in the general population. |
The Motley Fool
April 5, 2011
Brian Orelli |
Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva. |
American Family Physician
December 15, 2000 |
Antibiotics: When They Can and Can't Help Antibiotics are strong medicines that can stop some infections and save lives. When they aren't used the right way, antibiotics can cause more harm than good. You can protect yourself and your family by knowing when you should use antibiotics and when you should avoid them... |
Chemistry World
April 4, 2007
John Bonner |
Antibiotic Combinations Tackle Resistance Using combinations of certain antimicrobial compounds can favor the growth of non-resistant strains of bacteria at the expense of resistant ones. The surprising finding may provide a general strategy to help eradicate strains of bacteria that are resistant to antibiotic therapy. |
Chemistry World
February 6, 2013
Harriet Brewerton |
Diagnosing bacterial growth Antibiotics are used regularly for treating bacterial infections, but there is currently no quick and simple test to determine the most effective type or dose of antibiotic for a specific patient infection. |
The Motley Fool
March 25, 2009
Brian Orelli |
Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication. |
Chemistry World
February 12, 2015
Dinsa Sachan |
Target ignorance to tackle resistance After the discovery of the New Delhi metallo-beta-lactamase-1 (NDM-1) gene, which renders some bacteria resistant to most antibiotics, India has attracted global criticism for not being able to contain antibiotic resistance. |
The Motley Fool
September 2, 2010
Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases. |
IEEE Spectrum
February 2009
Monica Heger |
Computer-Designed Drugs Could Thwart Antibiotic-Resistant Bacteria Researchers use computer algorithms to tweak enzymes that make antibiotics |
Fast Company
May 2009
Elizabeth Svoboda |
Biotechs Wage War on Superbugs With antibiotic resistance on the rise, three biotechs are developing new ways to wage war on superbugs. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
January 20, 2004
David Nierengarten |
Adolor's Knocked-Out Drug The biotech's stock is pummeled after mixed-up trial results. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
April 5, 2011
Cindy Johnson |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Cubist Pharmaceuticals popped as much as 17% in intraday trading today after announcing a licensing agreement and the settlement of a patent dispute. |
American Family Physician
October 1, 2004 |
Antibiotics: When They Can and Can't Help An overview on how antibiotic therapy comes into play in the treatment of the flu and colds. |
AskMen.com
Jacob Franek |
Superbugs So long as antibiotic use remains widespread and excessive, superbug bacteria will be here with us. Read on about some of the most common North American superbugs. |
Nutrition Action Healthletter
November 1999
Michael F. Jacobson |
Fighting Superbugs For more than 30 years, doctors have used the antibiotic vancomycin when all others have failed. Now vancomycin itself is starting to fail, and its successor, synercid, is already encountering resistant germs. A change in U.S. agricultural policy may be able to stem that process... |
Chemistry World
October 29, 2015
Anthony King |
Poor diagnostics hinder battle against antibiotic resistance The tools used to diagnose bacterial infections have barely improved since the 1940s. |
